The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer.
The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer.
复制标题
DOI：
10.3389/fonc.2021.759595
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Yuan P
中科院分区：
文献类型：
--
作者：
Kang YK;Wang X;Hu NL;Yue J;Si YR;Ju J;Gao SL;Yuan P
本研究旨在评估和比较各种内分泌治疗对年轻乳腺癌患者血脂的影响。本研究采用回顾性单中心研究方法，观察他莫昔芬（TAM）、他莫昔芬+卵巢功能抑制剂（TAM+OFS）和芳香化酶抑制剂+卵巢功能抑制剂（AI+OFS）对40岁以下激素受体阳性的早期乳腺癌患者60个月内分泌治疗期间血脂水平的影响。主要终点是血脂事件的累积发生率，次要终点是血脂谱的变化。共纳入230例年轻患者，平均年龄为35.7岁。TAM组5年血脂事件发生率显著低于TAM+OFS组（7.4%vs21.3%，P=0.016）和AI+OFS组（7.4%vs21.6%，P=0.009）。TAM+OFS组的脂肪肝发生率显著高于TAM组（52.5%vs30.9%，P=0.043）。血脂事件与年龄较小相关（比值比（OR）=0.865，95%置信区间（CI）：0.780-0960; P=0.006），基线LDL-C较高（OR=14.959，95% CI：4.379-51.105; P<0.001），使用OFS（OR=3.557，95% CI：1.151-10.989; P=0.027）。因此，在年龄较小和基线LDL-C较高的情况下，应用OFS可能会增加绝经前乳腺癌中脂质事件的发生率。年轻乳腺癌患者在内分泌治疗中应注意血脂的变化。
This study aimed to evaluate and compare the effects of various endocrine therapies on lipid profiles in young patients with breast cancer. A retrospective, single-center study was performed to investigate the effects of tamoxifen (TAM), tamoxifen plus ovarian function suppression (TAM+OFS), and aromatase inhibitors plus ovarian function suppression (AI+OFS) on lipid profiles during the 60 months of endocrine therapy in hormone receptor-positive patients aged <40 with early breast cancer. The primary endpoint was the cumulative incidence of lipid events, and the secondary endpoints were the changes in lipid profiles. A total of 230 young patients were included with the mean age of 35.7 years old. The patients in TAM group had significantly lower incidence of 5-year lipid events than those in TAM+OFS group (7.4% versus 21.3%; P=0.016) and AI+OFS group (7.4% versus 21.6%; P=0.009). The incidence of fatty liver was significantly higher in TAM+OFS group than TAM group (52.5%versus 30.9%; P=0.043). Lipid events were associated with younger age (odds ratio (OR)=0.865, 95% confidence interval (CI): 0.780-0960; P=0.006), higher baseline LDL-C (OR=14.959, 95% CI: 4.379-51.105; P<0.001), and use of OFS (OR=3.557, 95% CI: 1.151-10.989; P=0.027). Therefore, application of OFS, with younger age and higher baseline LDL-C, may increase the incidence of lipid events in premenopausal breast cancer. More care should be taken for lipid profiles during the endocrine therapy for young breast cancer patients.
登录
查看更多内容
乳腺癌患者辅助化疗相关血脂变化的真实回顾性分析
影响因子：
1.6
作者：
He, Tao;Wang, Chengshi;Chen, Jie
通讯作者：
Chen, Jie
影响因子：
3.8
作者：
Song D;Hu Y;Diao B;Miao R;Zhang B;Cai Y;Zeng H;Zhang Y;Hu X
通讯作者：
Hu X
影响因子：
168.9
作者：
Davies, C.;Godwin, J.;Gray, R.;Clarke, M.;Darby, S.;McGale, P.;Wang, Y. C.;Peto, R.;Pan, H. C.;Cutter, D.;Taylor, C.;Ingle, J.
通讯作者：
Ingle, J.
DOI：
10.1056/nejmoa1404037
发表时间：
2014-07-10
期刊：
The New England journal of medicine
影响因子：
--
作者：
Pagani O;Regan MM;Walley BA;Fleming GF;Colleoni M;Láng I;Gomez HL;Tondini C;Burstein HJ;Perez EA;Ciruelos E;Stearns V;Bonnefoi HR;Martino S;Geyer CE Jr;Pinotti G;Puglisi F;Crivellari D;Ruhstaller T;Winer EP;Rabaglio-Poretti M;Maibach R;Ruepp B;Giobbie-Hurder A;Price KN;Bernhard J;Luo W;Ribi K;Viale G;Coates AS;Gelber RD;Goldhirsch A;Francis PA;TEXT and SOFT Investigators;International Breast Cancer Study Group
通讯作者：
International Breast Cancer Study Group
影响因子：
50.5
作者：
Hozumi, Y.;Suemasu, K.;Ohashi, Y.
通讯作者：
Ohashi, Y.